Microorganisms (Nov 2020)
Anti–SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study
- Evangelos Terpos,
- Marianna Politou,
- Theodoros N. Sergentanis,
- Andreas Mentis,
- Margherita Rosati,
- Dimitris Stellas,
- Jenifer Bear,
- Xintao Hu,
- Barbara K. Felber,
- Vassiliki Pappa,
- Maria Pagoni,
- Elisavet Grouzi,
- Stavroula Labropoulou,
- Ioanna Charitaki,
- Ioannis Ntanasis-Stathopoulos,
- Dimitra Moschandreou,
- Anthi Bouhla,
- Stylianos Saridakis,
- Eleni Korompoki,
- Chara Giatra,
- Tina Bagratuni,
- Angelos Pefanis,
- Sotirios Papageorgiou,
- Alexandros Spyridonidis,
- Anastasia Antoniadou,
- Anastasia Kotanidou,
- Konstantinos Syrigos,
- Konstantinos Stamoulis,
- George Panayiotakopoulos,
- Sotirios Tsiodras,
- Leonidas Alexopoulos,
- Meletios A. Dimopoulos,
- George N. Pavlakis
Affiliations
- Evangelos Terpos
- Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece
- Marianna Politou
- Hematology Laboratory Blood Bank, Aretaieion Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece
- Theodoros N. Sergentanis
- Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece
- Andreas Mentis
- Public Health Laboratories, Hellenic Pasteur Institute, 11521 Athens, Greece
- Margherita Rosati
- Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA
- Dimitris Stellas
- Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA
- Jenifer Bear
- Human Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA
- Xintao Hu
- Human Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA
- Barbara K. Felber
- Human Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA
- Vassiliki Pappa
- Hematology Unit, Second Department of Internal Medicine, Attikon University General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece
- Maria Pagoni
- BMT Unit, Department of Hematology and Lymphomas, Evangelismos General Hospital, 10676 Athens, Greece
- Elisavet Grouzi
- Department of Transfusion Service and Clinical Hemostasis, “Saint Savvas” Oncology Hospital, 11522 Athens, Greece
- Stavroula Labropoulou
- Public Health Laboratories, Hellenic Pasteur Institute, 11521 Athens, Greece
- Ioanna Charitaki
- Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece
- Ioannis Ntanasis-Stathopoulos
- Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece
- Dimitra Moschandreou
- Department of Transfusion Service and Clinical Hemostasis, “Saint Savvas” Oncology Hospital, 11522 Athens, Greece
- Anthi Bouhla
- Hematology Unit, Second Department of Internal Medicine, Attikon University General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece
- Stylianos Saridakis
- Blood Bank, Evangelismos General Hospital, 10442 Athens, Greece
- Eleni Korompoki
- Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece
- Chara Giatra
- BMT Unit, Department of Hematology and Lymphomas, Evangelismos General Hospital, 10676 Athens, Greece
- Tina Bagratuni
- Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece
- Angelos Pefanis
- Department of Internal Medicine, Sotiria General Hospital of Chest Diseases, 11527 Athens, Greece
- Sotirios Papageorgiou
- Hematology Unit, Second Department of Internal Medicine, Attikon University General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece
- Alexandros Spyridonidis
- BMT Unit, University Hospital of Patras, School of Medicine, University of Patras, 26500 Patras, Greece
- Anastasia Antoniadou
- Fourth Department of Internal Medicine, Attikon University General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece
- Anastasia Kotanidou
- First Department of Critical Care Medicine and Pulmonary Services, Evangelismos General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece
- Konstantinos Syrigos
- Oncology Unit, Third Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece
- Konstantinos Stamoulis
- Hellenic National Blood Transfusion Center, 13678 Athens, Greece
- George Panayiotakopoulos
- Pharmacology Laboratory, School of Medicine, University of Patras, 26500 Patras, Greece
- Sotirios Tsiodras
- Fourth Department of Internal Medicine, Attikon University General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece
- Leonidas Alexopoulos
- Biomedical Systems Laboratory, National Technical University of Athens, 11527 Athens, Greece
- Meletios A. Dimopoulos
- Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece
- George N. Pavlakis
- Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA
- DOI
- https://doi.org/10.3390/microorganisms8121885
- Journal volume & issue
-
Vol. 8,
no. 12
p. 1885
Abstract
We evaluated the antibody responses in 259 potential convalescent plasma donors for Covid-19 patients. Different assays were used: a commercial ELISA detecting antibodies against the recombinant spike protein (S1); a multiplex assay detecting total and specific antibody isotypes against three SARS-CoV-2 antigens (S1, basic nucleocapsid (N) protein and receptor-binding domain (RBD)); and an in-house ELISA detecting antibodies to complete spike, RBD and N in 60 of these donors. Neutralizing antibodies (NAb) were also evaluated in these 60 donors. Analyzed samples were collected at a median time of 62 (14–104) days from the day of first symptoms or positive PCR (for asymptomatic patients). Anti-SARS-CoV-2 antibodies were detected in 88% and 87.8% of donors using the ELISA and the multiplex assay, respectively. The multivariate analysis showed that age ≥50 years (p p p 60 days after symptom onset (p = 0.001) correlated with lower titers. Interestingly, pseudotype virus-neutralizing antibodies (PsNAbs) significantly correlated with spike and with RBD antibodies by ELISA. Sera with high PsNAb also showed a strong ability to neutralize active SARS-CoV-2 virus, with hospitalized patients showing higher titers. Therefore, convalescent plasma donors can be selected based on the presence of high RBD antibody titers.
Keywords
